Citadel Advisors
GNCA

Citadel Advisors’s Genocea Biosciences, Inc. GNCA Stock Holding History

Citadel Advisors’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,000
Closed -$15K – 14912
2022
Q1 		$15K Sell
12,000
-47,100
-80% -$51.3K ﹤0.01% 13322
2021
Q4 		$69K Sell
59,100
-51,900
-47% -$77.3K ﹤0.01% 13047
2021
Q3 		$213K Sell
111,000
-87,100
-44% -$171K ﹤0.01% 11865
2021
Q2 		$464K Buy
198,100
+34,800
+21% +$83.9K ﹤0.01% 10219
2021
Q1 		$443K Buy
163,300
+65,700
+67% +$195K ﹤0.01% 9954
2020
Q4 		$236K Buy
97,600
+75,100
+334% +$171K ﹤0.01% 9488
2020
Q3 		$52K Buy
22,500
+11,900
+112% +$31.2K ﹤0.01% 9596
2020
Q2 		$24K Buy
+10,600
New +$24.4K ﹤0.01% 9524
2018
Q4 		– Sell
-6,050
Closed -$38K – 10163
2018
Q3 		$38K Buy
6,050
+4,087
+208% +$21.6K ﹤0.01% 8867
2018
Q2 		$13K Buy
+1,963
New +$14.7K ﹤0.01% 8711
2018
Q1 		– Sell
-1,788
Closed -$17K – 9090
2017
Q4 		$17K Buy
+1,788
New +$18K ﹤0.01% 7856
2017
Q2 		– Sell
-2,250
Closed -$110K – 8392
2017
Q1 		$110K Buy
+2,250
New +$87.9K ﹤0.01% 6822

Other funds holding GNCA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Citadel Advisors's GNCA Position: Q2 2022 in Review

Citadel Advisors sold out of Genocea Biosciences, Inc. (GNCA) in Q2 2022, closing a stake of 1,843,112 shares — an estimated $2.3M sold.

Citadel Advisors first reported a position in GNCA in Q2 2017 and held it in 15 quarters. The position peaked at $4.96M in Q1 2021. 5 funds tracked by Wall St. Rank hold GNCA as of Q2 2022.

  • Citadel Advisors reported no remaining Genocea Biosciences, Inc. position as of Q2 2022 after selling out during the quarter.
  • Citadel Advisors sold 1,843,112 Genocea Biosciences, Inc. shares in Q2 2022, an estimated $2.3M.
  • Citadel Advisors first reported a position in Genocea Biosciences, Inc. in Q2 2017 and held it in 15 quarters.
  • Citadel Advisors's Genocea Biosciences, Inc. position peaked at $4.96M in Q1 2021.
  • 5 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q2 2022.

Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.